Therapeutic agent

Maraviroc

PreliminaryEvidence level
1Registered trials
1Conditions
0Study references

Evidence Summary

Evidence Level
Preliminary
Mechanism
Enrollment: Estimated, Sponsor Type: Industry, Unknown / General
Safety
Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.
Dosing
See linked studies/trials for reported doses and durations; typical protocols vary widely.
CCR5 antagonist studied for persistent immune activation (often + statin). 300mg BID; LFT monitoring. Very early/experimental for these conditions.

Clinical Trials

1 trial(s) registered

NCT IDTitlePhaseStatus
NCT06974084A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of thePhase 2Not yet recruiting

Key Studies / References

  • See linked studies